Fig. 4: MM-AT-NPs ameliorated plaque and inflammation in an atherosclerotic mouse model. | Nature Communications

Fig. 4: MM-AT-NPs ameliorated plaque and inflammation in an atherosclerotic mouse model.

From: Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines

Fig. 4: MM-AT-NPs ameliorated plaque and inflammation in an atherosclerotic mouse model.

a Representative photographs and quantitative analysis of aorta root sections stained by H&E, CD14 antibody, MMP-9 antibody, Masson’s trichrome, and α-SMA antibody (n = 6). Scale bar: 500 μm. b–d The levels of TNF-α, IL-1β, and IL-6 in aorta tissues collected from atherosclerotic mice after treatment with various formulations (saline, AT, AT-NPs, MM-AT-NPs, and AT-NPs/MAs) at a dose of 2 mg kg−1 AT per week (n = 6). e–g The levels of TNF-α, IL-6 and oxPL-LDL in blood serum (n = 6). h The levels of TC, HDL-C, and Non-HDL-C in the blood serum (n = 6). i The changes of body weight in atherosclerotic mice treated with various formulations (saline, AT, AT-NPs, MM-AT-NPs, and AT-NPs/MAs) (n = 7). All data were presented as mean ± s.d. Statistical analysis was conducted using one-way ANOVA. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. Source data are provided as a Source Data file.

Back to article page